Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

October 31, 2026

Conditions

β-thalassemia Major

Interventions

GENETIC

BD211

Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.

Trial Locations (1)

RECRUITING

Shanghai Ruijin Hospital, Shanghai

All Listed Sponsors

collaborator

Ruijin Hospital

OTHER

lead

Shanghai BDgene Co., Ltd.

INDUSTRY